Verrica Pharmaceuticals’ YCANTH Receives New Chemical Entity Status, Orange Book Listing From FDA
The Dermatology Digest
MARCH 26, 2024
Verrica Pharmaceuticals Inc.’s While NCE status will provide YCANTH with a minimum of five years of protection, we anticipate our full patent portfolio to provide protection from generic competition for the next decade and potentially beyond,” says Ted White, Verrica’s President and Chief Executive Officer, in a news release.
Let's personalize your content